Concepedia

Suzanne DeVandry

SD

Statistics

Publications

5

Citations

439

H-Index

5

Active since

2002

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Children's Hospital of Pittsburgh

Suzanne DeVandry is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in cancer research, clinical trials, and cancer therapeutics.

Top concepts

Publications per year

2002–2011

5

Publications

5

Single-Dose Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With Cisplatin Therapy: Randomized, Double-Blind Study Protocol—EASE

Steven M. Grunberg, Daniel T. T. Chua, Anish Maru et al. · Journal of Clinical Oncology · 2011 · 219 citations · Full text

Aprepitant in adolescent patients for prevention of chemotherapy‐induced nausea and vomiting: A randomized, double‐blind, placebo‐controlled study of efficacy and tolerability

Lia Gore, Sant P. Chawla, Antônio Sérgio Petrilli et al. · Pediatric Blood & Cancer · 2008 · 99 citations

Famotidine for infant gastro‐oesophageal reflux: a multi‐centre, randomized, placebo‐controlled, withdrawal trial

Susan R. Orenstein, Theresa M. Shalaby, Suzanne DeVandry et al. · Alimentary Pharmacology & Therapeutics · 2003 · 81 citations

Autosomal dominant infantile gastroesophageal reflux disease: exclusion of a 13q14 locus in five well characterized families

Susan R. Orenstein, Theresa M. Shalaby, Robert A. Finch et al. · The American Journal of Gastroenterology · 2002 · 25 citations

Phase III randomized double-blind study of single-dose fosaprepitant for prevention of cisplatin-induced nausea and vomiting.

Steven M. Grunberg, Dtt Chua, A Maru et al. · Journal of Clinical Oncology · 2010 · 15 citations

, , +14

1–5 of 5